Published in Proc Natl Acad Sci U S A on March 01, 1978
Spliced early mRNAs of simian virus 40. Proc Natl Acad Sci U S A (1978) 18.67
Simian virus 40 early mRNA's. I. Genomic localization of 3' and 5' termini and two major splices in mRNA from transformed and lytically infected cells. J Virol (1979) 5.93
Antibodies specific for the carboxy- and amino-terminal regions of simian virus 40 large tumor antigen. Proc Natl Acad Sci U S A (1980) 4.04
Splicing as a requirement for biogenesis of functional 16S mRNA of simian virus 40. Proc Natl Acad Sci U S A (1979) 3.89
Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J Virol (1979) 3.04
Shared antigenic determinants between two distinct classes of proteins in cells infected with herpes simplex virus. J Virol (1980) 2.62
Extraction and fingerprint analysis of simian virus 40 large and small T-antigens. J Virol (1978) 2.50
Nucleotide sequence analysis of viable deletion mutants lacking segments of the simian virus 40 genome coding for small t antigen. J Virol (1979) 2.28
Middle T antigen as primary inducer of full expression of the phenotype of transformation by polyoma virus. J Virol (1980) 1.96
Nucleotide sequence of the BK virus DNA segment encoding small t antigen. Proc Natl Acad Sci U S A (1979) 1.67
Characterization of two SV40 early mRNAs and evidence for a nuclear "prespliced" RNA species. Nucleic Acids Res (1978) 1.57
Genomic structure of human polyoma virus JC: nucleotide sequence of the region containing replication origin and small-T-antigen gene. J Virol (1983) 1.36
Characterization of tau antigens isolated from uninfected and simian virus 40-infected monkey cells and papovavirus-transformed cells. J Virol (1980) 1.25
Multiple forms of polyoma virus tumor antigens from infected and transformed cells. J Virol (1979) 1.04
Comparative analysis of GS and BK virus genomes. J Virol (1979) 0.95
Functional similarity between the early antigens of simian virus 40 and human papovavirus BK. J Virol (1979) 0.94
Characterization of the amino-terminal tryptic peptide of simian virus 40 small-t and large-T antigens. J Virol (1978) 0.92
Immunological cross-reactivity between simian virus 40 large T antigen and D2 hybrid T antigen. J Virol (1981) 0.85
BK virus DNA sequence coding for the t and T antigens and evaluation of methods for determining sequence homology. J Virol (1980) 0.82
Evolutionary relationships of the primate papovaviruses: base sequence homology among the genomes of simian virus 40, stump-tailed macaque virus, and SA12 virus. J Virol (1979) 0.81
Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. J Immunol (1975) 47.77
New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet (1971) 12.13
Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet (1971) 11.92
Regulation of tumor antigen synthesis by simain virus 40 gene A. J Virol (1975) 9.93
Construction and analysis of viable deletion mutants of simian virus 40. J Virol (1976) 9.11
Organization and expression of early genes of simian virus 40. Proc Natl Acad Sci U S A (1978) 7.10
Generation of avian myeloblastosis virus structural proteins by proteolytic cleavage of a precursor polypeptide. J Mol Biol (1975) 6.84
Cell-free translation of simian virus 40 early messenger RNA coding for viral T-antigen. Proc Natl Acad Sci U S A (1977) 6.57
Host range mutants of polyoma virus. Proc Natl Acad Sci U S A (1970) 5.68
Tumor antigen(s) in cell productively infected by wild-type polyoma virus and mutant NG-18. Proc Natl Acad Sci U S A (1978) 4.64
Anchorage and growth regulation in normal and virus-transformed cells. Int J Cancer (1968) 3.97
Characterization of polyoma virus T antigen. Proc Natl Acad Sci U S A (1977) 3.21
Human papovavirus (JC): induction of brain tumors in hamsters. Science (1973) 3.05
Two forms of simian-virus-40-specific T-antigen in abortive and lytic infection. Proc Natl Acad Sci U S A (1976) 2.67
Monomer molecular weight of T antigen from simian virus 40-infected and transformed cells. Proc Natl Acad Sci U S A (1976) 2.64
Fingerprints of polyoma virus proteins and mouse histones. Cold Spring Harb Symp Quant Biol (1975) 2.64
Human papovavirus, BK strain: biological studies including antigenic relationship to simian virus 40. J Virol (1973) 2.54
The use of protein A-containing Staphylococcus aureus as a solid phase anti-IgG reagent in radioimmunoassays as exemplified in the quantitation of alpha-fetoprotein in normal human adult serum. Eur J Immunol (1974) 2.19
The early region of SV40 DNA may have more than one gene. Cell (1977) 2.09
Common structural antigen of papovaviruses of the simian virus 40-polyoma subgroup. J Virol (1977) 2.02
Evidence for simian virus 40 (SV40) coding of SV40 T-antigen and the SV40-specific proteins in HeLa cells infected with nondefective adenovirus type 2-SV40 hybrid viruses. J Virol (1977) 1.94
Transformation of hamster kidney cells by BK papovavirus DNA. J Virol (1975) 1.81
Comparison of JC and BK human papovaviruses with simian virus 40: DNA homology studies. J Virol (1976) 1.51
Useful buffer and gel systems for polyacrylamide gel electrophoresis. Z Klin Chem Klin Biochem (1972) 1.44
Studies of nondefective Adenovirus 2-Simian virus 40 hybrid viruses. 8. Association of Simian virus 40 transplantation antigen with a specific region of the early viral genome. J Virol (1973) 1.42
Relationship between the methionine tryptic peptides of simian virus 40 and BK virus tumor antigens. J Virol (1977) 1.38
Polynucleotide sequences common to the genomes of simian virus 40 and the human papovaviruses JC and BK. Virology (1976) 1.25
Electron microscope study of the base sequence homology between simian virus 40 and human papovavirus BK. J Virol (1978) 1.23
Thin-layer gel filtration of proteins. I. Method. J Chromatogr (1968) 0.94
Identification of the human papovavirus T antigen and comparison with the simian virus 40 protein a. Virology (1977) 0.93
Specificity of the Tumor-specific transplantation antigen induced by JC virus, a human polyomavirus. Intervirology (1977) 0.80
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Quantitation of Simian virus 40 sequences in African green monkey, mouse and virus-transformed cell genomes. J Mol Biol (1971) 7.10
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science (1988) 6.30
The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol (1990) 6.08
A rapid method for detecting and mapping homology between heterologous DNAs. Evaluation of polyomavirus genomes. J Biol Chem (1979) 5.32
Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol (1998) 5.31
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol (1992) 5.05
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
A map of simian virus 40 transcription sites expressed in productively infected cells. J Mol Biol (1973) 5.02
Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A (1986) 4.89
Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A (1986) 4.43
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol (1996) 4.08
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90
Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol (1989) 3.90
Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol (1993) 3.90
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Patterns of Simian Virus 40 DNA transcription after acute infection of permissive and nonpermissive cells. Proc Natl Acad Sci U S A (1972) 3.65
Genetic recombination of human immunodeficiency virus. J Virol (1989) 3.61
The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol (1989) 3.36
SV40 gene activity during lytic infection and in a series of SV40 transformed mouse cells. Proc Natl Acad Sci U S A (1969) 3.30
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA (1991) 3.25
Identification of ecotropic proviral sequences in inbred mouse strains with a cloned subgenomic DNA fragment. Proc Natl Acad Sci U S A (1980) 3.19
Molecular cloning of polyoma virus DNA in Escherichia coli: lambda phage vector system. Science (1979) 3.17
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol (1994) 3.07
Envelope and long terminal repeat sequences of a cloned infectious NZB xenotropic murine leukemia virus. J Virol (1985) 3.06
Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes. J Virol (1992) 3.06
Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells. J Virol (1979) 3.04
Characterization of murine leukaemia virus-specific DNA present in normal mouse cells. Nat New Biol (1973) 2.98
Translation of Sindbis virus 26 S RNA and 49 S RNA in lysates of rabbit reticulocytes. J Mol Biol (1974) 2.97
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96
Replication of Sindbis virus. II. Multiple forms of double-stranded RNA isolated from infected cells. J Mol Biol (1972) 2.88
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem (1995) 2.70
Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis (1997) 2.60
Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J Virol (1989) 2.60
Replication of Sindbis virus. I. Relative size and genetic content of 26 s and 49 s RNA. J Mol Biol (1972) 2.59
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med (1999) 2.53
Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol (1995) 2.43
Nucleotide sequence of a full-length human endogenous retroviral segment. J Virol (1985) 2.36
Characterization of polyoma viral DNA sequences in polyoma-induced hamster tumor cell lines. J Biol Chem (1980) 2.33
Thermal stabilities and species specificities of reannealed animal deoxyribonucleic acids. Biochemistry (1966) 2.32
Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation. J Virol (1991) 2.30
Transcription of novel open reading frames of AIDS retrovirus during infection of lymphocytes. Science (1985) 2.28
Identification and cloning of endogenous retroviral sequences present in human DNA. Proc Natl Acad Sci U S A (1981) 2.26
Physical map of the BK virus genome. J Virol (1975) 2.18
Endogenous murine leukemia proviral long terminal repeats contain a unique 190-base-pair insert. Proc Natl Acad Sci U S A (1983) 2.10
Cloning and characterization of an envelope-specific probe from xenotropic murine leukemia proviral DNA. J Virol (1982) 2.09
Specific hybridization probes demonstrate fewer xenotropic than mink cell focus-forming murine leukemia virus env-related sequences in DNAs from inbred laboratory mice. J Virol (1986) 2.08
Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing. Virology (1991) 2.05
Patterns of simian virus 40 deoxyribonucleic acid transcription. II. In transformed cells. J Virol (1973) 2.04
Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol (1998) 2.01
mRNA transcripts related to full-length endogenous retroviral DNA in human cells. Nature (1984) 1.94
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. J Virol (1994) 1.92
Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol (1998) 1.90
Increased future ice discharge from Antarctica owing to higher snowfall. Nature (2012) 1.88
Heterogeneity of murine leukemia virus in vitro DNA; detection of viral DNA in mammalian cells. Science (1971) 1.88
Characterization of a molecularly cloned retroviral sequence associated with Fv-4 resistance. J Virol (1985) 1.87
Prognosis of physicians treated for alcoholism and drug dependence. JAMA (1984) 1.82
Transformation of hamster kidney cells by BK papovavirus DNA. J Virol (1975) 1.81
Characterization of human papovavirus BK DNA. J Virol (1975) 1.81
Homology and relationship between the genomes of papovaviruses, BK virus and simian virus 40. Proc Natl Acad Sci U S A (1975) 1.81
An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences. J Virol (1994) 1.81
HIV-1 infection of non-dividing cells. Nature (1994) 1.79
Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol (2010) 1.78
Zenker's diverticula: pathophysiology, clinical presentation, and flexible endoscopic management. Dis Esophagus (2008) 1.76
Molecular characterization of a polymerase mutant human immunodeficiency virus. Virology (1987) 1.76
Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses (1996) 1.74
Molecular cloning of polyoma virus DNA in Escherichia coli: plasmid vector system. Science (1979) 1.74
Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views. Health Technol Assess (2000) 1.74
Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus. J Virol (2000) 1.73
Relationship among Tau antigens isolated from various lines of simian virus 40-transformed cells. J Virol (1980) 1.72
Aryl hydrocarbon hydroxylase activity in the fungus Cunninghamella bainieri: evidence for the presence of cytochrome P-450. Arch Biochem Biophys (1976) 1.71
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol (1997) 1.71
Biological activity of polyoma viral DNA in mice and hamsters. J Virol (1979) 1.70
Distinctive termini characterize two families of human endogenous retroviral sequences. Science (1984) 1.69
Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. J Virol (1992) 1.68
Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science (1993) 1.68
Molecular organization of the AIDS retrovirus. Cell (1985) 1.65
Deoxyribonucleic acid homologies among some bacteria. J Bacteriol (1967) 1.63
DNA-binding region of the simian virus 40 tumor antigen. J Virol (1986) 1.62
Characterization of proviruses cloned from mink cell focus-forming virus-infected cellular DNA. J Virol (1982) 1.60
Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. JAMA (1989) 1.59